Van Dyke beard Van Dyke beard A Van Dyke (sometimes spelled Vandyke, or Van Dyck) is a style of facial hair named after the 17th-century Flemish painter Anthony van Dyck (1599–1641). A Van Dyke specifically consists of any growth of both a moustache and goatee with all hair on the cheeks shaven. Even this particular style, though, has many variants, including a curled moustache versus a non-curled one and a soul patch versus none. The style is sometimes called a "Charlie" after King Charles I of England, who was painted with this type of beard by van Dyck. "Pike-devant" or "pickedevant" are other
Christopher H. van Dyck brain. Studies of this ligand in early Alzheimer’s Disease patients have shown a loss of synapses from the perforant path, the connections between the entorhinal cortex and hippocampal formation needed for memory consolidation. van Dyck and the Yale ADRU have tested potential Alzheimer’s therapeutics for over 20 years. They have contributed to the successful development of memantine now in use for the treatment of mid-late stage Alzheimer’s Disease, and assess potential new therapeutic strategies, e.g. antibodies that reduce amyloid pathology such as Crenezumab, and based on the work of Dr. Stephen Strittmatter, an inhibitor of fyn. Dr. van Dyck serves